Interferon alpha2b induced dopamine changes in Cutaneous Melanoma patients
Objective. The authors interest was focused on interferon impact on dopamine status and on the relation between negative emotional state and dopamine in melanoma patients. Methods. 60 patients diagnosed with malignant melanoma in 1st or 2nd clinical stage were included in the first 56 days after su...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Amaltea Medical Publishing House
2015-12-01
|
| Series: | Romanian Journal of Neurology |
| Subjects: | |
| Online Access: | https://rjn.com.ro/articles/2015.4/RJN_2015_4_Art-06.pdf |
| _version_ | 1811257855451332608 |
|---|---|
| author | Corina-Daniela Ene Ilinca Nicolae |
| author_facet | Corina-Daniela Ene Ilinca Nicolae |
| author_sort | Corina-Daniela Ene |
| collection | DOAJ |
| description | Objective. The authors interest was focused on interferon impact on dopamine status and on the relation between negative emotional state and dopamine in melanoma patients.
Methods. 60 patients diagnosed with malignant melanoma in 1st or 2nd clinical stage were included in the first 56 days after surgical removal of the tumor in an observational prospective study. The patients were divided in 2 groups: group A that included 30 cases treated with 10MU interferon alpha2b/mp three times a week for one year and group B that included 30 cases with no adjuvant treatment. Urinary dopamine (ELISA) was evaluated before treatment with interferon alpha2b, after 1, 6, 12 months of treatment and after 6 months from the end of the treatment.
Neuropsychiatric disorders were grouped according to their frequency in melanoma patients.
Results. Neuropsychiatric disorders associated with the treatment with interferon were: irritability, asthenia and fatigability, sleep disorders, anxiety, cognitive disorders, somatic symptoms. The treatment with interferon altered dopamine metabolism. Dopamine returned to the pretherapeutical values at six months after interferon was stopped. Patients with low levels of urinary dopamine had a high, statistically significant risk of developing depression during interferon treatment (OR=2.647, IC=2.186-3.014, p=0.0216).
Conclusions. Low dopamine might have a major role in the development of depression secondary to interferon treatment. |
| first_indexed | 2024-04-12T18:04:04Z |
| format | Article |
| id | doaj.art-23fa5b80aee947489a8d149a8a59039d |
| institution | Directory Open Access Journal |
| issn | 1843-8148 2069-6094 |
| language | English |
| last_indexed | 2024-04-12T18:04:04Z |
| publishDate | 2015-12-01 |
| publisher | Amaltea Medical Publishing House |
| record_format | Article |
| series | Romanian Journal of Neurology |
| spelling | doaj.art-23fa5b80aee947489a8d149a8a59039d2022-12-22T03:22:03ZengAmaltea Medical Publishing HouseRomanian Journal of Neurology1843-81482069-60942015-12-0114421922410.37897/RJN.2015.4.6Interferon alpha2b induced dopamine changes in Cutaneous Melanoma patientsCorina-Daniela Ene0Ilinca Nicolae1“Carol Davila” Clinical Hospital of Nephrology, Bucharest, RomaniaResearch Department in Dermatology, “Victor Babes” Clinical Hospital of Tropical and Infectious Diseases, Bucharest, RomaniaObjective. The authors interest was focused on interferon impact on dopamine status and on the relation between negative emotional state and dopamine in melanoma patients. Methods. 60 patients diagnosed with malignant melanoma in 1st or 2nd clinical stage were included in the first 56 days after surgical removal of the tumor in an observational prospective study. The patients were divided in 2 groups: group A that included 30 cases treated with 10MU interferon alpha2b/mp three times a week for one year and group B that included 30 cases with no adjuvant treatment. Urinary dopamine (ELISA) was evaluated before treatment with interferon alpha2b, after 1, 6, 12 months of treatment and after 6 months from the end of the treatment. Neuropsychiatric disorders were grouped according to their frequency in melanoma patients. Results. Neuropsychiatric disorders associated with the treatment with interferon were: irritability, asthenia and fatigability, sleep disorders, anxiety, cognitive disorders, somatic symptoms. The treatment with interferon altered dopamine metabolism. Dopamine returned to the pretherapeutical values at six months after interferon was stopped. Patients with low levels of urinary dopamine had a high, statistically significant risk of developing depression during interferon treatment (OR=2.647, IC=2.186-3.014, p=0.0216). Conclusions. Low dopamine might have a major role in the development of depression secondary to interferon treatment.https://rjn.com.ro/articles/2015.4/RJN_2015_4_Art-06.pdfdopamineinterferon alpha2bmelanomaneuropsychiatric disorders |
| spellingShingle | Corina-Daniela Ene Ilinca Nicolae Interferon alpha2b induced dopamine changes in Cutaneous Melanoma patients Romanian Journal of Neurology dopamine interferon alpha2b melanoma neuropsychiatric disorders |
| title | Interferon alpha2b induced dopamine changes in Cutaneous Melanoma patients |
| title_full | Interferon alpha2b induced dopamine changes in Cutaneous Melanoma patients |
| title_fullStr | Interferon alpha2b induced dopamine changes in Cutaneous Melanoma patients |
| title_full_unstemmed | Interferon alpha2b induced dopamine changes in Cutaneous Melanoma patients |
| title_short | Interferon alpha2b induced dopamine changes in Cutaneous Melanoma patients |
| title_sort | interferon alpha2b induced dopamine changes in cutaneous melanoma patients |
| topic | dopamine interferon alpha2b melanoma neuropsychiatric disorders |
| url | https://rjn.com.ro/articles/2015.4/RJN_2015_4_Art-06.pdf |
| work_keys_str_mv | AT corinadanielaene interferonalpha2binduceddopaminechangesincutaneousmelanomapatients AT ilincanicolae interferonalpha2binduceddopaminechangesincutaneousmelanomapatients |